Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 6/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9959902 | 0.98 | HSD11B1 (0.35) | HSD11B1MEN1ALDH1A1MAPTPKM | |
| SCHEMBL15569945 | 0.72 | PLK1 (0.44) | — | |
| SCHEMBL31739495 | 0.71 | HTR2C (0.33) | HSD11B1MEN1ALDH1A1MAPTPKM | |
| SCHEMBL3771294 | 0.70 | HSD11B1 (0.38) | HSD11B1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL3764595 | 0.70 | HSD11B1 (0.38) | HSD11B1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL23852144 | 0.69 | BTK (0.35) | HSD11B1MEN1ALDH1A1MAPTPKM | |
| SCHEMBL30793500 | 0.69 | ALOX15 (0.32) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL5469025 | 0.68 | PLK1 (0.44) | — | |
| SCHEMBL21672584 | 0.68 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL18237386 | 0.68 | DRD4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655371-B1 | PYRAZOLOPIPERIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-8546442-B2 | Pyrazolopiperidine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546442-B2 | Pyrazolopiperidine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20120322790-A1 | Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322790-A1 | Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012087782-A1 | PYRAZOLOPIPERIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322790-A1 | Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | HSD11B1 2283/4885MEN1 3429/4885ALDH1A1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.